Skip to search formSkip to main contentSkip to account menu

carfilzomib

Known as: (2S)-N-((1S)-1-Benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide 
An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the… 
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (1)

Kyprolis
NCIt Antineoplastic Agent TerminologyPR-171Proteasome Inhibitors [MoA]carfilzomib 60 MG Injection [Kyprolis]

Broader (1)

Oligopeptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and…
INTRODUCTION. Bortezomib, lenalidomide and dexamethasone (VRd) is considered a standard of care combination therapy for newly… 
2019
2019
Randomized phase 3 study of carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible , NDMM patients Running title : KMP vs VMP for newly diagnosed multiple myeloma
250 Text: 4000/4000 Figures/tables: 5/4 (total = 9) References: 32/100 Blood First Edition Paper, prepublished online February 28… 
2016
2016
Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).
8005Background: Isatuximab (ISA) is a humanized anti-CD38 monoclonal antibody with multiple modes of action for killing tumor… 
2016
2016
Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed…
Introduction In a phase 1/2 study designed to assess KRd w/o ASCT, KRd provided a high rate of stringent complete response (sCR… 
2016
2016
Inhibition of chymotryptic-like standard proteasome activity exacerbates doxorubicin-induced cytotoxicity in primary cardiomyocytes.
Review
2013
Review
2013
Diagnosis and therapy of multiple myeloma
Many advances in the treatment of multiple myeloma have been made due to the use of transplantation and the introduction of novel… 
2012
2012
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
Abstract 74 Background: Carfilzomib, a novel proteasome inhibitor (PI), and pomalidomide, an immunomodulatory agent (IMiD), have… 
2011
2011
Elucidation of the α-keto-aldehyde binding mechanism: a lead structure motif for proteasome inhibition.
Lead role: The role of peptidyl alpha-keto aldehydes as proteasome inhibitors is well established, yet their molecular binding… 
Review
2011
Review
2011
Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
Proteasome inhibition forms the cornerstone of antimyeloma therapy. The first-in-class proteasome inhibitor, bortezomib, either… 
Review
2005
Review
2005
Stem cell transplantation in multiple myeloma
Single autologous transplantation High-dose treatment (HDT) with autologous stem cell transplantation (ASCT) has been shown to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)